Pegylated IFN- alpha 2b + Ribavirin
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Hepatitis C
Conditions
Hepatitis C
Trial Timeline
Apr 1, 2002 → Apr 1, 2007
NCT ID
NCT00277862About Pegylated IFN- alpha 2b + Ribavirin
Pegylated IFN- alpha 2b + Ribavirin is a approved stage product being developed by Tempus AI for Hepatitis C. The current trial status is completed. This product is registered under clinical trial identifier NCT00277862. Target conditions include Hepatitis C.
What happened to similar drugs?
20 of 20 similar drugs in Hepatitis C were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00277862 | Approved | Completed |
Competing Products
20 competing products in Hepatitis C
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| VK2809 + Placebos | Viking Therapeutics | Phase 2 | 32 |
| TERN-501 + TERN-101 | Terns Pharmaceuticals | Phase 2 | 32 |
| TERN-101 | Terns Pharmaceuticals | Phase 2 | 32 |
| TERN-201 | Terns Pharmaceuticals | Phase 1 | 26 |
| IVA337 + IVA337 + Placebo | Inventiva | Phase 2 | 29 |
| IVA337 + Placebo + Empagliflozin | Inventiva | Phase 2 | 29 |
| IVA337 + Placebo | Inventiva | Phase 3 | 41 |
| Pegasys® + Pegasys® | Chugai Pharmaceutical | Approved | 43 |
| peginterferon alfa-2a + rivavirin | Chugai Pharmaceutical | Phase 3 | 40 |
| SOF + COPE | Chugai Pharmaceutical | Pre-clinical | 26 |
| Colesevelam Hcl | Daiichi Sankyo | Phase 2 | 35 |
| ASP9831 + Placebo | Astellas Pharma | Phase 2 | 35 |
| FK788 | Astellas Pharma | Phase 2 | 35 |
| MK-2248 | Merck | Phase 1 | 29 |
| Interferon alfacon-1 | Astellas Pharma | Phase 3 | 40 |
| Pegylated Interferon + Ribavirin | Astellas Pharma | Approved | 35 |
| Tacrolimus + steroids, monoclonal anti-IL2R antibody | Astellas Pharma | Phase 2 | 35 |
| Dolutegravir + Rlipivirine + GSK1265744 | Shionogi | Phase 1 | 29 |
| Dolutegravir + Methadone | Shionogi | Phase 1 | 29 |
| Clevudine + Adefovir | Eisai | Phase 3 | 40 |